Silence Therapeutics
25 hedge funds and large institutions have $116M invested in Silence Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 26 → 25 (-1)
6.07% less ownership
Funds ownership: 40.71% → 34.64% (-6.1%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
91% less capital inflows, than outflows
Capital inflows: $3.4M | Capital outflows: $37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (USA)
New York
|
+$1.63M |
| 2 |
Cantor Fitzgerald
New York
|
+$458K |
| 3 |
UBS O'Connor
Chicago,
Illinois
|
+$350K |
| 4 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$319K |
| 5 |
WM
WS Management
Jacksonville,
Florida
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
-$29.7M |
| 2 |
Goldman Sachs
New York
|
-$3.72M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.07M |
| 4 |
Great Point Partners
Greenwich,
Connecticut
|
-$522K |
| 5 |
Legal & General Group
London,
United Kingdom
|
-$288K |
SLN Hedge Fund Activity: Q2 2022 in Review
25 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2022, worth a combined $116M — down 47% from $218M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SLN and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was Lombard Odier Asset Management (USA), adding an estimated $1.63M. The largest seller was Lombard Odier Asset Management (Europe), exiting entirely with an estimated $29.7M sold.
- 25 institutional investors held Silence Therapeutics (SLN) as of Q2 2022, down from 26 in Q1 2022.
- Funds reported $116M of Silence Therapeutics stock for Q2 2022, down 47% quarter-over-quarter.
- 4 funds opened new Silence Therapeutics positions in Q2 2022 and 5 closed out, a net change of -1 holder.
- The largest Silence Therapeutics buyer in Q2 2022 was Lombard Odier Asset Management (USA), an estimated $1.63M added.
- The largest Silence Therapeutics seller in Q2 2022 was Lombard Odier Asset Management (Europe), an estimated $29.7M sold.
Based on aggregated 13F filings for Q2 2022.